Collectively, these results suggest that in a subset of melanoma cells, chronic BRAF inhibitor treatment can cause epigenetic adaptation that involves PPARGC1A suppression and acquisition of aggressive melanoma traits. The gene discussed is PPARGC1A; the disease is melanoma.